FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076124116> ?p ?o ?g. }

• W2076124116 endingPage "134" @default.
• W2076124116 startingPage "125" @default.
• W2076124116 abstract "5-lipoxygenase (5-LOX)-activating protein, 5-LOXAP also known as LOX5AP or FLAP, is a protein that works closely with 5-LOX in regulating the metabolism of arachidonate. Some of the eicosanoid products of 5-LOX/5-LOXAP are known to play active roles in the function of cancer cells, including breast cancer cells. The current study investigated the expression of 5-LOXAP in clinical breast cancer and the prognostic impact of 5-LOXAP and 5-LOX in patients with breast cancer. A cohort of breast tumour tissues (n = 122) with normal background tissues (n = 32) were investigated. 5-LOXAP and 5-LOX transcripts were determined using RT-PCR and quantitative RT-PCR. Levels of the transcripts were analysed against clinical and pathological information. Breast tumour tissues had significantly higher levels of 5-LOX transcript compared with normal tissues (P = 0.015). The transcript was seen at significantly higher levels in node positive tumours than that in node negative tumours (P = 0.02). The prognostic significance was assessed using both a prognostic index and clinical outcome. Value of 5-LOXAP was first demonstrated when using the Nottingham Prognostic Index (NPI) as an indicator, in that patients with predicted poor prognosis had significantly higher levels of 5-LOXAP than patients with good prognosis (P = 0.0407). Furthermore, patients who died of breast cancer-related causes had significant higher levels of 5-LOXAP than those patients who remained disease free, following a median 10-year followup. A survival analysis has shown that high levels of 5-LOXAP were significantly correlated with overall survival (mean survival 109.6 month vs. 139.4 months, in tumour from patients with high and low levels of 5-LOXAP, P = 0.05). The same disadvantage of high levels of 5-LOXAP was also seen with disease-free survival (105.2 months vs. 135.6 months, P = 0.017). Analysis of 5-LOXAP together with 5-LOX transcript did not enhance the significance of the survival. However, when 5-LOXAP was considered together with 12-LOX, it improved the predictive power for both overall and disease-free survival (109.0 month vs. 143.1 months, P = 0.0156 for overall survival and 98.3 months vs. 141.3 months for disease-free survival, P = 0.0022). In conclusion, 5-LOXAP expression was aberrant in human breast cancer, particularly in aggressive tumours. Furthermore, 5-LOXAP had a significant prognostic value in patients with breast cancer. This identifies 5-LOXAP as a potential therapeutic target in breast cancer." @default.
• W2076124116 created "2016-06-24" @default.
• W2076124116 creator A5017993198 @default.
• W2076124116 creator A5058372074 @default.
• W2076124116 creator A5082900326 @default.
• W2076124116 date "2006-02-01" @default.
• W2076124116 modified "2023-10-16" @default.
• W2076124116 title "Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer" @default.
• W2076124116 cites W1973598581 @default.
• W2076124116 cites W1973784980 @default.
• W2076124116 cites W1980706097 @default.
• W2076124116 cites W1990404670 @default.
• W2076124116 cites W1992137818 @default.
• W2076124116 cites W1993274317 @default.
• W2076124116 cites W1994862373 @default.
• W2076124116 cites W1995783979 @default.
• W2076124116 cites W2014768234 @default.
• W2076124116 cites W2019266913 @default.
• W2076124116 cites W2035093916 @default.
• W2076124116 cites W2038575244 @default.
• W2076124116 cites W2042102227 @default.
• W2076124116 cites W2048861137 @default.
• W2076124116 cites W2050669947 @default.
• W2076124116 cites W2054044627 @default.
• W2076124116 cites W2067480565 @default.
• W2076124116 cites W2073202677 @default.
• W2076124116 cites W2076677873 @default.
• W2076124116 cites W2083419879 @default.
• W2076124116 cites W2123171103 @default.
• W2076124116 cites W2128172426 @default.
• W2076124116 cites W2135247813 @default.
• W2076124116 cites W2138305526 @default.
• W2076124116 cites W2149517485 @default.
• W2076124116 cites W2150966393 @default.
• W2076124116 cites W2151341807 @default.
• W2076124116 cites W2156021383 @default.
• W2076124116 cites W2160234181 @default.
• W2076124116 cites W4241607739 @default.
• W2076124116 doi "https://doi.org/10.1016/j.plefa.2005.10.005" @default.
• W2076124116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16364620" @default.
• W2076124116 hasPublicationYear "2006" @default.
• W2076124116 type Work @default.
• W2076124116 sameAs 2076124116 @default.
• W2076124116 citedByCount "51" @default.
• W2076124116 countsByYear W20761241162012 @default.
• W2076124116 countsByYear W20761241162013 @default.
• W2076124116 countsByYear W20761241162014 @default.
• W2076124116 countsByYear W20761241162015 @default.
• W2076124116 countsByYear W20761241162016 @default.
• W2076124116 countsByYear W20761241162017 @default.
• W2076124116 countsByYear W20761241162018 @default.
• W2076124116 countsByYear W20761241162019 @default.
• W2076124116 countsByYear W20761241162020 @default.
• W2076124116 countsByYear W20761241162021 @default.
• W2076124116 countsByYear W20761241162022 @default.
• W2076124116 crossrefType "journal-article" @default.
• W2076124116 hasAuthorship W2076124116A5017993198 @default.
• W2076124116 hasAuthorship W2076124116A5058372074 @default.
• W2076124116 hasAuthorship W2076124116A5082900326 @default.
• W2076124116 hasConcept C121608353 @default.
• W2076124116 hasConcept C126322002 @default.
• W2076124116 hasConcept C142724271 @default.
• W2076124116 hasConcept C143998085 @default.
• W2076124116 hasConcept C207886595 @default.
• W2076124116 hasConcept C2778001805 @default.
• W2076124116 hasConcept C2779740036 @default.
• W2076124116 hasConcept C530470458 @default.
• W2076124116 hasConcept C63363279 @default.
• W2076124116 hasConcept C71924100 @default.
• W2076124116 hasConcept C90924648 @default.
• W2076124116 hasConceptScore W2076124116C121608353 @default.
• W2076124116 hasConceptScore W2076124116C126322002 @default.
• W2076124116 hasConceptScore W2076124116C142724271 @default.
• W2076124116 hasConceptScore W2076124116C143998085 @default.
• W2076124116 hasConceptScore W2076124116C207886595 @default.
• W2076124116 hasConceptScore W2076124116C2778001805 @default.
• W2076124116 hasConceptScore W2076124116C2779740036 @default.
• W2076124116 hasConceptScore W2076124116C530470458 @default.
• W2076124116 hasConceptScore W2076124116C63363279 @default.
• W2076124116 hasConceptScore W2076124116C71924100 @default.
• W2076124116 hasConceptScore W2076124116C90924648 @default.
• W2076124116 hasIssue "2" @default.
• W2076124116 hasLocation W20761241161 @default.
• W2076124116 hasLocation W20761241162 @default.
• W2076124116 hasOpenAccess W2076124116 @default.
• W2076124116 hasPrimaryLocation W20761241161 @default.
• W2076124116 hasRelatedWork W150871787 @default.
• W2076124116 hasRelatedWork W2101673433 @default.
• W2076124116 hasRelatedWork W2224319365 @default.
• W2076124116 hasRelatedWork W2354400911 @default.
• W2076124116 hasRelatedWork W2362580737 @default.
• W2076124116 hasRelatedWork W2363705548 @default.
• W2076124116 hasRelatedWork W2391631919 @default.
• W2076124116 hasRelatedWork W2897588803 @default.
• W2076124116 hasRelatedWork W3010070186 @default.
• W2076124116 hasRelatedWork W377899687 @default.
• W2076124116 hasVolume "74" @default.
• W2076124116 isParatext "false" @default.

• next